drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
Autologous genetically engineered CD22-directed chimeric antigen receptor (CAR) T-cell therapy administered after lymphodepleting chemotherapy to treat relapsed/refractory B-cell lymphomas by targeting and eliminating CD22-expressing B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered ex vivo to express a chimeric antigen receptor that recognizes CD22 on B cells. Upon CD22 binding, the CAR transmits activation and co-stimulatory signals, driving T‑cell activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytolysis, resulting in targeted depletion of CD22‑expressing malignant (and normal) B cells.
drug_name
CD22CART
nct_id_drug_ref
NCT06340737